World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   681 records for 180 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4 5 6 7 8 9 10 Last
Recruitment statusProspective RegistrationMain ID Public TitleDate of RegistrationResults available
RecruitingNoPACTR201711002800419
Vitamin A status in tuberculous children
27/11/2017 
RecruitingYesNCT03371017
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
Recruitment statusMain IDPublic titleDate of registrationResults available
AuthorisedEUCTR2016-005119-42-HU A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients with Early Relapsing Recurrent Triple-Negative Breast Cancer 23/11/2017Yes
21/11/2017 
Not RecruitingYesCTRI/2017/11/010315
To compare the efficacy and the safety of Masitinib versus placebo in the treatment of patients with severe Asthma
01-11-2017Yes
Not RecruitingYesCTRI/2017/10/010010
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131)
05-10-2017Yes
RecruitingNoCTRI/2017/09/009894
Heat therapy(agnikarma) in Tennis Elbow
22-09-2017Yes
AuthorisedYesEUCTR2017-001409-34-SI
A Study of Atezolizumab to investigate long term safety and efficacy in patients with locally advanced or metastatic non small cell lung cancer (NSCLC)
Recruitment statusMain IDPublic titleDate of registrationResults available
AuthorisedEUCTR2017-001409-34-ES A Study of Atezolizumab to investigate long term safety and efficacy in patients with locally advanced or metastatic non small cell lung cancer (NSCLC) 02/10/2017 
AuthorisedEUCTR2017-001409-34-LV A Study of Atezolizumab to investigate long term safety and efficacy in patients with locally advanced or metastatic non small cell lung cancer (NSCLC) 20/09/2017 
AuthorisedEUCTR2017-001409-34-SE A Study of Atezolizumab to investigate long term safety and efficacy in patients with locally advanced or metastatic non small cell lung cancer (NSCLC) 14/09/2017 
AuthorisedEUCTR2017-001409-34-DK A Study of Atezolizumab to investigate long term safety and efficacy in patients with locally advanced or metastatic non small cell lung cancer (NSCLC) 18/09/2017 
AuthorisedEUCTR2017-001409-34-PL A Study of Atezolizumab to investigate long term safety and efficacy in patients with locally advanced or metastatic non small cell lung cancer (NSCLC) 20/09/2017 
AuthorisedEUCTR2017-001409-34-NL A Study of Atezolizumab to investigate long term safety and efficacy in patients with locally advanced or metastatic non small cell lung cancer (NSCLC) 02/10/2017 
RecruitingPER-029-17 A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (TAIL) 18/01/2018 
RecruitingNCT03285763 A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) 14/09/2017 
22/08/2017Yes
RecruitingYesDRKS00012686
Smartphone-based intervention (S.M.I.L.E.R.S.) to reduce mild to moderate depressive symptoms in Arabic-speaking clients
21/08/2017 
Not recruitingNoNCT03176238
Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
01/06/2017 
RecruitingYesNCT03125902
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
Recruitment statusMain IDPublic titleDate of registrationResults available
AuthorisedEUCTR2016-004024-29-FR A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Paclitaxel Compared with Placebo with Paclitaxel for Patients with Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer 27/06/2017 
AuthorisedEUCTR2016-004024-29-ES A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Paclitaxel Compared with Placebo with Paclitaxel for Patients with Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer 15/09/2017 
AuthorisedEUCTR2016-004024-29-GR A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Paclitaxel Compared with Placebo with Paclitaxel for Patients with Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer 08/06/2017 
AuthorisedEUCTR2016-004024-29-CZ A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Paclitaxel Compared with Placebo with Paclitaxel for Patients with Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer 02/06/2017Yes
AuthorisedEUCTR2016-004024-29-DE A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Paclitaxel Compared with Placebo with Paclitaxel for Patients with Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer 24/05/2017Yes
AuthorisedEUCTR2016-004024-29-SK A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Paclitaxel Compared with Placebo with Paclitaxel for Patients with Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer 02/05/2017Yes
20/04/2017 
RecruitingNoNCT03024554
Evaluation of Safety and Efficacy of the Bifurcated Multilayer Flow Modulator (BMFM®).
05/01/2017 
      
1 2 3 4 5 6 7 8 9 10 Last
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history